Performance and Verification of a Real-Time PCR Assay Targeting the gyrA Gene for Prediction of Ciprofloxacin Resistance in Neisseria gonorrhoeae
- PMID: 26739156
- PMCID: PMC4767994
- DOI: 10.1128/JCM.03032-15
Performance and Verification of a Real-Time PCR Assay Targeting the gyrA Gene for Prediction of Ciprofloxacin Resistance in Neisseria gonorrhoeae
Abstract
In the United States, 19.2% of Neisseria gonorrhoeae isolates are resistant to ciprofloxacin. We evaluated a real-time PCR assay to predict ciprofloxacin susceptibility using residual DNA from the Roche Cobas 4800 CT/NG assay. The results of the assay were 100% concordant with agar dilution susceptibility test results for 100 clinical isolates. Among 76 clinical urine and swab specimens positive for N. gonorrhoeae by the Cobas assay, 71% could be genotyped. The test took 1.5 h to perform, allowing the physician to receive results in time to make informed clinical decisions.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
References
-
- Centers for Disease Control and Prevention. 2015. Sexually transmitted disease surveillance 2014. Centers for Disease Control and Prevention, Atlanta, GA.
-
- Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA.
-
- Centers for Disease Control and Prevention. 2012. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61:590–594. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
